Cabozantinib in genitourinary malignancies.

Published

Journal Article (Review)

Cabozantinib inhibits a variety of cellular receptors including VEGFR1-3, MET, AXL, RET, FLT3 and KIT. These signaling pathways have been shown to be important in genitourinary malignancies. Along its clinical development, it has shown most activity in advanced renal cell carcinoma; the METEOR study compared cabozantinib to everolimus and showed clinically and statistically significant improvements in both progression-free survival and overall survival. Herein, we review the development of cabozantinib in the genitourinary malignancies of renal cell carcinoma, prostate adenocarcinoma and urothelial carcinoma.

Full Text

Duke Authors

Cited Authors

  • Zhang, T; Park, SE; Hong, C; George, DJ

Published Date

  • April 2017

Published In

Volume / Issue

  • 13 / 8

Start / End Page

  • 755 - 765

PubMed ID

  • 27842445

Pubmed Central ID

  • 27842445

Electronic International Standard Serial Number (EISSN)

  • 1744-8301

Digital Object Identifier (DOI)

  • 10.2217/fon-2016-0358

Language

  • eng

Conference Location

  • England